COVID-19
Conditions
Brief summary
This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine
Detailed description
This study is a randomized and controlled phase Ⅳ clinical trial in children aged 3-5 years old. The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine.The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.A total of 520 subjects aged 3-5 years old will be enrolled.Subjects will be randomly divided into 2 groups in a ratio of 1:1.The experimental group is the combined immunization group, which will receive the first dose of COVID-19 vaccine and the second dose of COVID-19 vaccine and EV71 vaccine on day 28;Control group is the Non-combined immunization group , which will receive the first dose of COVID-19 vaccine on day 0 ，the first dose of EV71 vaccine on day 14 ，the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
Interventions
BIOLOGICALExperimental Group
The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
BIOLOGICALControl Group
The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Sponsors
Sinovac Research and Development Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 5 Years
Healthy volunteers
Yes
Inclusion criteria
* Children aged 3-5 years ; * The subject and/or guardian can understand and voluntarily sign the informed consent form * Proven legal identity;
Exclusion criteria
* History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days; * History of multiple system inflammatory syndrome (MIS-C); * History of hand, foot and mouth disease, herpetic angina or EV71 vaccination; * History of asthma, history of allergy to the vaccine or vaccine components,or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema; * Congenital malformations or developmental disorders, genetic defects,severe malnutrition, etc.; * Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency / immunosuppression(HIV,history after organ transplantation)； * Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition; * Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy,abnormal platelets) or obvious bruising or blood coagulation; * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; * History of drug abuse; * Receipt of blood products within in the past 3 months; * Receipt of other investigational drugs in the past 30 days; * Receipt of attenuated live vaccines in the past 14 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Axillary temperature \>37.0°C; * The subjects participated in other clinical trials during the follow-up period, or will be planned within 3 months; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity index-Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 | Day 28 after the second dose of COVID-19 vaccine | Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine |
| Immunogenicity index-Seroconversion rate of the neutralizing antibody to EV71 | Day 28 after the second dose of EV71 vaccine | Seroconversion rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 vaccine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71 | Day 28 after the second dose of EV71 | Seropositive rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 |
| Immunogenicity index-GMT of the neutralizing antibody to EV71 | Day 28 after the second dose of EV71 | GMT of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 |
| Immunogenicity index-GMI of the neutralizing antibody to EV71 | Day 28 after the second dose of EV71 | GMI of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 |
| Safety index-Incidence of the adverse reactions | From day 0 to day 7 after each dose | Incidence of the adverse reactions from day 0 to day 7 after each dose |
| Safety index-Incidence of the serious adverse events and the adverse events of special interest | From the beginning vaccination to 6 months after the last dose | Incidence of the serious adverse events and the adverse events of special interest from the beginning vaccination to 6 months after the last dose |
| Immunogenicity index-Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 | Day 28 after the second dose of COVID-19 vaccine | Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine. |
| Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2 | Day 28 after the second dose of COVID-19 vaccine | GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine. |
| Immunogenicity index-GMI of the neutralizing antibody to live SARS-CoV-2 | Day 28 after the second dose of COVID-19 vaccine | GMI of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity index-GMT of the neutralizing antibody to EV71 | 6 months after the second dose of EV71 vaccine | GMT of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine. |
| Immunogenicity index-Seropositive rate of the neutralizing antibody to live SARS-CoV-2 | 6 months after the second dose of COVID-19 vaccine | Seropositive rate and GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine |
| Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71 | 6 months after the second dose of EV71 vaccine | Seropositive rate of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine |
| Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2 | 6 months after the second dose of COVID-19 vaccine | GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine |
Countries
China
Outcome results
None listed